Login
ORAMED PHARMACEUTICALS INC. logo

ORAMED PHARMACEUTICALS INC.

oramed.com

What Do They Do?

Develops pharmaceutical solutions using a platform for oral delivery of therapeutic proteins, and invests in healthcare and life sciences companies.

How Do They Make Money?

The company received payments under its HTIT technology license; the remaining deferred amount counted as revenue after HTIT waived claims in connection with the joint venture agreement.

FY2025 revenue

Who Are Their Customers?

HTIT was the licensee for Oramed’s oral insulin capsule, with rights to commercialize it in China, Macau and Hong Kong.

Do Revenues Turn Into Profits?

Yes. Its net income in FY2025 was larger than its revenue, but spent more cash than it brought in: free cash flow was −$9.2M.

Operating income, FY2025
−754% of revenue
▼ −18% (Loss) vs FY2024 (−$12.8M)
Net income, FY2025
3203% of revenue
▲ Turned profitable vs FY2024 (−$19.1M)
Free cash flow, FY2025
−458% of revenue
▼ −9% (Loss) vs FY2024 (−$8.4M)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −62%
vs $48.4M in Q3 FY2025
  • Mar 31, 2026 Lifeward completed its acquisition of Oratech Oramed received Lifeward shares and warrants, plus revenue-sharing payments tied to ReWalk personal exoskeleton products and related warranties.

Shrinking. Revenue fell 26% in 4 years, from $2.7M in FY2021 to $2M in FY2025, about 7% a year.

Strategic investments The latest report adds strategic investing alongside pharmaceutical research and development, including capital allocation to healthcare and life sciences companies.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support